Nineteen years of experience utilizing anti-t-lymphocyte globulin induction in pediatric kidney transplantation

Annals of Transplantation

Volumn 15, Issue 4, 2010, Pages 84-91

  Mota, Conceicao ^a   Martins, Lassalete ^a   Costa, Teresa ^a   Dias, Leonidio ^a   Almeida, Manuela ^a   Santos, Josefina ^a   Sameiro Faria, M ^a   Castro Henriques, A ^a   Almeida, Rui ^a  

^a Centro Hospitalar Universitario do Porto   (Portugal)

Author keywords

Deceased donor; Immunosuppression; Pediatric renal transplantation

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CEFOXITIN; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; FRESENIUS; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; OKT 3; PREDNISOLONE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; PNEUMOCYSTOSIS; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PROPHYLAXIS; SCHOOL CHILD; THYROID CARCINOMA; VIRUS INFECTION;

ADOLESCENT; ANTILYMPHOCYTE SERUM; CHILD; FEMALE; FOLLOW-UP STUDIES; GLOBULINS; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78651233496     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Olaitan OK, Zimmermann JA, Shields WP et al: Long-term outcome of intensive initial immunosuppression protocol in pediatric deceased donor renal transplantation. Pediatr Transplant, 2009: 1-6
2. Mota C, Henriques C, Sarmento M et al: Kidney transplantation in pediatric population. Transplant Proc, 1994; 26(5): 2768-2770
3. Bunchman TE, Ham JM, Sedman AB et al: Superior allograft survival in pediatric renal transplant recipients. Transplant Proc, 1994; 26(1): 24-25
4. NAPRTCS Annual report. Available from: https://web.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf. Accessed November 2009
5. Lange H, Müller TF, Ebel H et al: Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Transpl Int, 1999; 12(1): 2-9
6. Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT: Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation, 2007; 84(1): 75-82
7. Kaden J: Eleven years intraoperative ATG bolus. A list of successes. Ann Transplant, 2002; 7(3): 4-10
8. Samsel R, Pliszczyński J, Chmura A et al: Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients - long term results. Ann Transplant, 2008; 13(1): 32-39
9. Müller TF, Grebe SO, Neumann MC et al: Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation, 1997; 64(10): 1432-1437
10. Martins L, Fonseca I, Almeida M et al: Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc, 2005; 37(6): 2755-2758
11. Civati G, Minetti E, Busnach G et al: Low incidence of acute rejection in kidney grafts treated with initial quadruple therapy: a retrospective analysis comparing two ATGs. Transplant Proc, 1998; 30(4): 1343-1345
12. Cardella CJ, Pierratos A: The effect of rabbit antithymocyte serum and pre-transplant transfusion on graft survival. Transplant Proc, 1982; 14(4): 623-626
13. Ducloux D, Kazory A, Challier B et al: Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation, 2004; 77(7): 1029-1033
14. Wang D, Chen JH, Wu WZ et al: One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients. Transplant Proc, 2007; 39(1): 69-72
15. Yang SL, Wang D, Wu WZ et al: Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Transpl Immunol, 2008; 18: 281-285
16. Opelz G, Naujokat C, Daniel V et al: Disassociation between risk of graft loss and risk of non- Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation. 2006; 81(9): 1227-1233
17. Ghods AJ, Nasrollahzadeh D: Noncompliance with immunnosuppressive medications after renal transplantation. Exp Clin Transplant. 2003; 1(1): 39-47
18. Delucchi A, Gutierrez H, Arrellano P et al: Factors that influence nonadherence in immunosuppressant treatment in pediatric transplant recipients: a proposal for an educational strategy. Transplant Proc, 2008; 40(9): 3241-3243
19. Harambat J, Cochat P: Growth after renal transplantation. Pediatr Nephrol, 2009; 24(7): 1297-1306
20. Broyer M, Le Bihan C, Charbit M et al: Long-term social outcome of children after kidney transplantation. Transplantation, 2004; 77(7): 1033-1037
21. Grenda R, Watson A, Trompeter R et al: A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: The TWIST study. Am J Transplant, 2010; 10(4): 828-8236